Dr. med. Joachim Köchling

1980	Abitur in Wolfhagen
1980 - 1981	Grundwehrdienst als Sanitäter in Marburg und Wolfhagen
1982 - 1983	Studium der Biochemie an der Freien Universität Berlin
1983 - 1987	Studium der Medizin an der Freien Universität Berlin
1987 - 1988	Studium der Medizin in Großbritannien - University of Edinburgh - University London (Guy's und St. Thomas's Medical School)
1988 - 1991	Studium der Medizin an der Freien Universität Berlin
1993	Ärztliche Approbation
1993	Promotion an der Freien Universität Berlin: "Pharmakokinetik und Pharmakodynamik von rekombinantem humanem Erythropoetin bei Hämodialysepatienten"
2005	Zusatzbezeichnung Notfallmedizin
2009	Facharztprüfung: Facharzt für Kinder- und Jugendmedizin
2012	Prüfung des Schwerpunktbereichs Päd. Hämatologie u. Onkologie
2015	Zusatzbezeichnung Pädiatrische Ernährungsmedizin

 

1992 – 1994	Abteilung für Kinderchirurgie, Freie Universität Berlin
1994 – 1996	Tufts University and New England Medical Center (NMEC), Boston, USA
1997 – 2000	Klinik für Pädiatrie, Charité, Campus Virchow-Klinikum, Berlin
2001 – 2001	Abteilung für Innere Medizin, Stadtkrankenhaus Bad Arolsen
2002 – 2003	Kinderklinik der Eberhard Karls Universität Tübingen
2003 – 2005	Abteilung für Innere Medizin, Stadtkrankenhaus Bad Arolsen
2006 –2011	Klinik für Kinder- und Jugendmedizin, UKSH, Campus Lübeck
2012 – 2015	Arbeit als Notarzt und Honorararzt
2015 – dato	Praxis für Kinder- und Jugendmedizin in Bad Segeberg

1994 – 1996	Ausbildungsstipendium der Deutschen Forschungsgemeinschaft
1996	Ausbildungsstipendium des NMEC, Tufts University Boston, USA
1997 – 2000	Forschungsförderung der Charité
2002 – 2004	Forschungsstipendium der Wilhelm Sander Stiftung
2003	Forschungsförderung der Universitätskinderklinik Tübingen
2005 – 2010	Forschungsstipendium der Deutschen José Carreras Leukämie-Stiftung
2008 – 2010	Forschungsförderung durch die Lübeck-Hilfe für krebskranke Kinder
2009 – 2010	Forschungsförderung der Universitätskinderklinik Lübeck

Brockmöller J, Köchling J, Weber W, Looby M, Roots I, Neumayer HH (1992) The pharmacokinetics and pharmacodynamics of recombinant human erythropoietin in hemodialysis patients. Br J Clin Pharmacol 34(6): 499-508

Köchling J, Pistor G, Märzhäuser-Brands S, Nasir R, Lanksch WR (1996) The Currarino Syndrome - Heriditary transmitted syndrome of anorectal, sacral and presacral anomalies. Case report and review of the literature. Eur J Pediatr Surg 6(2): 114-119

Köchling J, Curtin PT, Madan A (1998): Regulation of human erythropoietin gene induction by upstream flanking sequences in transgenic mice. Br J Haematol 103(4): 960-968

Korte A, Möricke A, Beyermann B, Köchling J, Taube T, Kebelmann-Betzing C, Henze G, Seeger K (1999) Extensive alternative splicing of interleukin-7 in malignant hematopoietic cells: Implication of distinct isoforms in modulating IL-7 activity. J Interferon Cytokine Res 19(5): 495-503

Seeger K, Buchwald D, Taube T, Peter A, von Stackelberg A, Schmitt G, Köchling J, Henze G (1999) TEL-AML1 positivity in relapsed B cell precursor acute lymphoblastic leukemia in childhood. Leukemia 13(9): 1469-1470

Korte A, Köchling J, Badiali L, Eckert C, Andreae J, Geilen W, Kebelmann-Betzing C, Taube T, Wu S, Henze G, Seeger K (2000) Expression analysis and characterization of alternatively spliced transcripts of human IL-7Ra chain encoding two truncated receptor proteins in relapsed childhood ALL. Cytokine 12(11): 1597-1608

Einsiedel HGV, Taube T, Beyermann B, Dragon S, Möricke A, Kebelmann-Betzig C, Köchling J, Henze G, Seeger K (2001) Absence of mutations in the CDKN2 binding site of CDK4 in childhood acute lymphoblastic leukemia. Leuk Lymphoma 40(3-4): 413-417

Kebelmann-Betzing C, Körner G, Badiali L, Buchwald D, Möricke A, Korte A, Köchling J, Wu S, Kappelmeier D, Oettel K, Henze G, Seeger K (2001) Characterization of cytokine, growth factor receptor, costimulatory and adhesion molecule expression pattern of bone marrow blasts in relepsed childhood B-cell precursor ALL. Cytokine 13(1): 39-50

Köchling J, Kabasiyan M, Reis A (2001) Spectrum of mutations and genotype-phenotype analysis in Currarino Syndrome. Eur J Hum Genet 9(8): 599-605

Köchling J, König Merediz SA, Stripecke R, Buchwald D, Korte A, von Einsiedel HG, Sack F, Henze G, Seeger K, Wittig B, Schmidt M (2003) Protection of mice against Ph+ acute lymphoblastic leukaemia by cell-based vaccination using non-viral, minimalistic expression vectors and immunomodulatory oligonucleotides. Clin Cancer Res 9(8): 3142-3149

Maia AT, Koechling J, Corbett R, Metzler M, Wiemels JL, Greaves M (2004) Protracted postnatal natural histories in childhood leukemia. Genes Chromosomes Cancer 39(4): 335-340

Riebel T, Kochling J, Scheer I, Oellinger J, Reis A (2004) Currarino syndrome: Variability of imaging findings in 22 moleculargenetically identified HLXB9 mutation patients from five families. Rofo 176(4): 564-569

Zuna J, Ford AM, Peham M, Patel N, Saha V, Eckert C, Köchling J, Panzer-Grümayer R, Trka J, Greaves M (2004) TEL deletion analysis supports a novel view of relapse in childhood acute lymphoblastic leukemia. Clin Cancer Res 10(16): 5355-5360

Köchling J, Freitag HJ, Bollinger T, Herz A, Sperner J (2008) Neuroborreliosis with Lymphocytic Meningitis and Unilateral Trigeminal Nerve Palsy: Follow Up of MRI and Serological Findings. Eur J Paediatr Neurol 12(6): 501 – 504

Köchling J, Prada JJ, Bahrami M, Stripecke R, Seeger K, Henze G, Wittig B, Schmidt M (2008) Anti-tumor effect of DNA-based vaccination and dSLIM immunomodulatory molecules in mice with Ph+ acute lymphoblastic leukaemia. Vaccine 26(36): 4669-4675

Köchling J, Rott Y, Arndt S, Marschke C, Schmidt M, Wittig B, Kalies K, Westermann J, Henze G (2012) Prevention and synergistic control of Ph+ ALL by a DNA vaccine and 6-mercaptopurine. Vaccine 30(41): 5949-5955

Köchling J,  Schmidt M, Rott Y, Sagner M, Ungefroren H, Wittig B, Henze G (2013)  Can anthocyanins improve maintenance therapy of Ph+ acute lymphoblastic leukemia?  Eur J Haematol 90: 291–300.

Köchling J, Hatch II SL, Madan A, Curtin PT (1995) Desoxyribonuclease I hypersensitive site in erythropoietin transgenic mice suggests the location of a regulatory element. Blood 86: 312a

Köchling J, Curtin PT, Madan A (1997) Mapping the kidney-specific inducible element upstream of the human erythropoietin gene. Blood 90: 309a

Seeger K, Buchwald D, Beyermann B, Adams HP, Köchling J, Schmid HJ, Niemeyer C, Janka G, Henze G, for the BFM relapse study group (1997) TEL-AML1 fusion transcript in relapsed childhood acute lymphoblastic leukemia (ALL). Blood 90: 560a

Köchling J, Madan A, Curtin PT (1998) A new functional HIF-1 binding site upstream of the human erythropoietin gene. Blood 92: 208a

Seeger K, Kreuzer KA, Schmidt CA, Buchwald D, Lass U, Schmitt G, Taube T, Kochling J, Beyermann B, Huhn D, Henze G (1998) Novel 5’ exonuclease-based real time PCR assay for the detection of TEL-AML1 fusion in childhood acute lymphoblastic leukemia (ALL). Blood 92: 392a

Seeger K, Buchwald D, Köchling J, Beyermann B, Möricke A, Schmitt G, Hanel C, Götze G, Henze G (1998) CBFA2/ETV6 fusion in ETV6/CBFA2 positive childhood ALL. Medical and Pediatric Oncology 31: 295

Curtin PT, Wang Z, Madan A, Köchling J (1999) An hypoxia-inducible regulatory element is present 9.2 kb upstream of the human erythropoietin gene. Blood 94: 261a

Köchling J, König Merediz SA, Sack F, Stripecke R, Buchwald D, Badiali, L, Schmid H, Henze G (1999) Gene therapy of PH⁺ ALL by DNA immunization and leukemic cell vaccines in a syngeneic mouse model. Blood 94: 411b

Korte A, Seeger K, Möricke A, Beyermann B, Köchling J, Taube T, Kebelmann-Betzing C, Henze G (1999) High diversity of splicing-derived interleukin-7 isoforms in acute lymphoblastic leukemia. Haematologica 84: 8a

Kebelmann-Betzing C, Schmitt G, Badiali L, Buchwald D, Möricke A, Köchling J, Wu S, Korte A, Schmid H, Henze G, Seeger K (1999) Cytokine, growth factor receptor, costimulatory and adhesion molecule expression pattern in relapsed childhood B-cell precursor ALL bone marrow blasts. Blood 94: 220b

Korte A, Badiali L, Köchling J, Schmid H, Geilen W, Eckert C, Kebelmann-Betzing C, Henze G, Seeger K (1999) IL-7Ra expression of leukemic cells and identification of two alternatively spliced transcripts encoding different truncated IL-7Ra proteins in childhood ALL. Blood 94: 72a

Seeger K, Kreuzer KA, Buchwald D, Taube T, Lass U, Schmitt G, Köchling J, Schmidt CA, Henze G (1999) Novel 5'exonuclease-based real-time PCR assay for the detection of TEL-AML1 fusion in childhood ALL. Klin Pädiatr 211: 377

Seeger KH, Wu S, Köchling J, Taube T, Geilen W, Buchwald D, Schmid HJ, Henze G (1999) Bone marrow stromal and lymphoblastic cells show distinct cytokine gene expressions and differential responses to SCF and IL-7 in childhood ALL. Blood 94: 72a

Curtin PT, Wang Z, Köchling J (2000) Conserved sequences upstream of the mouse erythropoietin gene suggests the presence of an additional hypoxia-responsive regulatory element. Blood 96: 131b

Köchling J, König Merediz SA, Wittig B, Stripecke R, Korte A, Seeger K, Taube T, Wu S, Schmid H, Henze G (2000) In-vivo transfection of murine skin with a novel expression vector encoding BCR-ABL breakpoint specific peptides prevents Ph⁺ ALL. Blood 96: 800a

Wu S, Andreae J, Korte A, Hanel C, Köchling J, Schmid H, Henze G, Seeger K (2000) Prednisolone inhibits the expression of cytokines and surface adhesion molecules of human bone marrow stromal cells in childhood ALL. Blood 96: 169b

Köchling J, Bahrami M, Stripecke R, Wittig B, Henze G, Seeger K, Schmidt M (2003) Optimization of DNA vaccine strategies protects mice against syngeneic Ph+ ALL. Blood 102: 746a

Riebel T, Köchling J, Scheer I, Oellinger H, Reis A (2003) Currarino triad: variability of immaging findings in 23 moleculargenetically identified patients. Pediatric Radiology 33 (Suppl 2): S30

Zuna J, Ford A, Peham M, Patel N, Saha V, Eckert C, Köchling J, Panzer-Grumayer R, Trka J, Greaves M (2003) Recurrence of TEL/AML1-positive ALL - Relapse or a new disease? Blood 102: 140a

Köchling J, Prada J, Bahrami M, König-Merediz SA, Stripecke R, Seeger K, Henze G, Wittig B,  Schmidt M (2006) BCR-ABL specific sequences are required to prevent Ph⁺ acute lymphoblastic leukemia in syngeneic mice by DNA vaccination. Blood 108: 931a

Köchling J, Rott Y, Arndt S, Green J, Anderson D, Langer R, Stripecke R, Wittig B, Schmidt M (2007) Prevention of Ph⁺ acute lymphoblastic leukemia by nanoparticulate delivery of a DNA vaccine in syngeneic mice. Blood 110: 5135a

Köchling J, Rott Y, Arndt S, Green J, Anderson D, Langer R, Stripecke R, Schmidt M, Henze G, Bucsky P (2008) Prevention of Ph⁺ acute lymphoblastic leukaemia by DNA vaccination using a non-viral vector system and nanoparticle delivery. Eur J Paed 167: 371

Rott Y, Arndt S, Green J, Anderson D, Stripecke R, Schmidt M, Wittig B, Köchling J (2008) Opimization of a BCR-ABL specific DNA vaccine against Ph+ ALL using a nonviral vector system and nanoparticle delivery. Blood 112: 4625

Rott Y, Arndt S, Green J, Stripecke R, Wittig B, Schmidt M, Köchling J (2009) CD8+ T cells and natural killer cells are essential for the immunization by a BCR-ABL-specific DNA vaccine against Ph+ ALL. Mol Ther 17: S155

Rott Y, Arndt S, Marschke C, Stripecke R, Wittig B, Schmidt M, Köchling J (2009) Synergism between Imatinib mesylate and a BCR-ABL-specific DNA vaccine against pre-established Ph⁺ acute lymphoblastic leukemia in syngeneic mice. Blood 114: 1201

Rott Y, Köchling J (2010) Synergismus von BCR-ABL spezifischer DNA-Vakzine und Imatinib als Rezidivprophylaxe bei Ph+ akuter lymphoblastischer Leukämie im syngenen Mausmodell. Pädiatrie hautnah 22: 266-267, P43

Rott Y, Schmidt M, Wittig B, Herting E, Köchling J (2010) Synergism between chemotherapy with 6-mercaptopurine and DNA vaccination against Ph⁺ acute lymphoblastic leukemia in syngeneic mice. Blood 116: 1338

Rott Y, Sagner M, Ungefroren H, Schmidt M, Wittig B, Herting E, Köchling J (2010) Antileukemic efficacy of anthocyanins in-vitro and in-vivo and in combination with a DNA vaccine against Ph⁺ acute lymphoblastic leukemia. Blood 116: 1339

Rott Y, Arndt S, Marschke C, Lauten M, Schmidt M, Wittig B, Kalies K, Westermann J, Köchling J (2011) Highly efficient treatment of Ph⁺ acute lymphoblastic leukemia with a DNA vaccine and 6-mercaptopurine in mice. Mol Ther 19: S195

Rott Y, Lauten M, Ungefroren H, Sagner M, Schmidt M, Wittig B, Köchling J (2011) Berry extract enhances a leukemia specific DNA vaccine in the treatment of minimal residual disease in mice with Ph⁺ ALL. Mol Ther 19: S195-196´